Bli medlem
Bli medlem

Du är här

2016-07-22

Immunicum AB: Immunicum AB Announces Appointment of Chief Medical Officer, Peter Suenaert, M.D., Ph.D.

Gothenburg, Sweden, July 22, 2016 - Immunicum AB (publ), a biopharmaceutical
company pursuing to develop sophisticated, safe and efficient therapeutic
cancer treatments with powerful and long lasting immune responses, announced
today that Peter Suenaert, M.D., Ph.D., has accepted the offer to take the
role as the Company's Chief Medical Officer (CMO). In this role, Dr. Suenaert
will oversee preclinical and clinical development of the Company's
immunotherapies pipeline of three diversified technology platforms COMBIG,
CD70 and Ad5PTDf35-adenovirus vector.

"Peter brings a wealth of clinical development expertise to Immunicum during
an exciting time in our company's growth," said Jamal El-Mosleh, Chief
Executive Officer of Immunicum. "In addition to the recent announcement of
our global clinical trials development collaboration with Accelovence, the
recruitment of a CMO with Peter's background represents another important
step in the evolution of Immunicum. With Peter's 14 years of clinical and
preclinical development experience with a variety of early and late stage
oncology/cancer immunotherapeutic products, we believe we are well positioned
to continue advancing our proprietary platforms, including our lead product
INTUVAX, through the clinical process and ultimately, to patients."

Prior to joining Immunicum, Dr. Suenaert served as Global Clinical Program
Lead for oncology and Senior Director of Clinical Sciences at Glenmark
Pharmaceuticals R&D in London, where he was heading up the clinical oncology
unit (immune oncology assets) from start-up stage to being fully operational
phase I/II protocol development.

Prior to that role, he was Director and Head of Clinical Development and Human
Translational Research, a position with global reach, and member of the
global management team Life Science at Danone Research in Palaiseau (Paris),
France. Previously, Dr. Suenaert was Clinical Research and Development Leader
in global early cancer immunotherapeutics development at GlaxoSmithKline
Vaccines in Rixensart, Belgium and Clinical Research Senior Medical
Scientist, Global Development, Haematology / Oncology at AMGEN in the U.K.

"Immunicum's novel three platform technologies for cancer immune priming,
adoptive immunotherapy and oncolytic treatment have the potential to deliver
truly transformative therapies," said Dr. Suenaert. "Our lead product
INTUVAX, an off-the-shelf cancer immune primer, has the ability to offer
personalized treatment, targeting solid tumors with the potential for success
in many indications. The product addresses cancer in ways that have not been
possible to-date and significantly widens the therapeutic index. I am excited
by the potential of Immunicum's offerings to pursue areas of treatment
currently with great unmet medical need. Given the promising clinical data
that has been gathered to date, I am looking forward to advancing our
pipeline and realizing our vision of bringing safer, more effective therapies
to patients."

For further information, please contact:

Jamal El-Mosleh, CEO, Immunicum

Phone: +46 (0) 31 41 50 52
jamal.el-mosleh@immunicum.com

The Company's Certified Adviser is Redeye AB

Phone: +46 (0) 8 545 013 31.www.redeye.se

About INTUVAX

INTUVAX is a cancer immune primer, developed for the treatment of solid
tumors. Its active ingredient is activated white blood cells, so called
dendritic cells, derived from healthy blood donors. Intratumoral injection of
these cells is expected to lead to an inflammatory response which in turn
leads to tumor-specific activation of the patient's cytotoxic T lymphocytes.

About Immunicum AB (publ)

Immunicum AB (publ) is working to develop and advance cancer immune primers
for the treatment of tumor diseases. A clinical phase II trial for the
Company's most advanced product - INTUVAX® against kidney cancer - has been
initiated. The project portfolio contains additional clinical phase I/II
studies in liver cancer and in gastrointestinal stromal tumors (GIST).

For more information, please visitwww.immunicum.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire

HUG#2030183

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.